09:26 AM EDT, 06/27/2024 (MT Newswires) -- NLS Pharmaceutics ( NLSP ) said Thursday that preclinical results from in vitro studies targeting alpha-synuclein, specifically the A53T mutation, showed the compounds' potential to treat Parkinson's disease.

NLS said it may use the compounds under a licensing deal with Aexon Labs.

The company said the in vitro results from Aexon Labs preclinical compounds, discovered through NLS' next-generation non-sulfonamide dual orexin agonist platform, showed "positive effects" on neurite outgrowth.

NLS shares were rising past 94% in recent premarket activity.

Price: 0.3555, Change: +0.17, Percent Change: +94.69